21![HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ALDURAZYME safely and effectively. See full prescribing information for ALDURAZYME. ALDURAZYME (LARONIDASE) Solution HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ALDURAZYME safely and effectively. See full prescribing information for ALDURAZYME. ALDURAZYME (LARONIDASE) Solution](https://www.pdfsearch.io/img/8d93de04fd7dcda38b7c429cabfe1d5a.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2013-04-09 13:51:10
|
---|
22![NDA[removed]S034 Approval Letter Page 5 of 26 Integrilin (eptifibatide) Injection For Intravenous Administration NDA[removed]S034 Approval Letter Page 5 of 26 Integrilin (eptifibatide) Injection For Intravenous Administration](https://www.pdfsearch.io/img/0ad405d76cd992883122ebc4076a9fcd.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2011-04-01 15:40:41
|
---|
23![Pharmacology / Research / Design of experiments / Evaluation methods / Bioethics / Eptifibatide / Placebo-controlled study / Clinical trial / Percutaneous coronary intervention / Medicine / Clinical research / Science Pharmacology / Research / Design of experiments / Evaluation methods / Bioethics / Eptifibatide / Placebo-controlled study / Clinical trial / Percutaneous coronary intervention / Medicine / Clinical research / Science](/pdf-icon.png) | Add to Reading ListSource URL: www.fda.govLanguage: English - Date: 1998-03-13 11:19:29
|
---|
24![APPROVAL OF REPLAGAL™ WITH CONDITIONS Conditional marketing approval has been granted for Replagal™ for the following indications: Replagal shows promising preliminary evidence of efficacy for the treatment of patien APPROVAL OF REPLAGAL™ WITH CONDITIONS Conditional marketing approval has been granted for Replagal™ for the following indications: Replagal shows promising preliminary evidence of efficacy for the treatment of patien](https://www.pdfsearch.io/img/35f4a8839cb2659bf28eb5ad33da9aad.jpg) | Add to Reading ListSource URL: www.hc-sc.gc.caLanguage: English - Date: 2013-07-12 14:26:09
|
---|
25![Drug Profiles Table of Contents Revised[removed]ABCIXIMAB Acetylsalicylic Acid, aspirin, ASA Acetylsalicylic Acid, aspirin, ASA EMT Administration Adenosine Drug Profiles Table of Contents Revised[removed]ABCIXIMAB Acetylsalicylic Acid, aspirin, ASA Acetylsalicylic Acid, aspirin, ASA EMT Administration Adenosine](https://www.pdfsearch.io/img/39780bbc877dbeee1a03b734ceb4fd5f.jpg) | Add to Reading ListSource URL: www.azdhs.govLanguage: English - Date: 2014-01-28 18:47:15
|
---|
26![Dear Health Care Professional Letter Natrecor Dear Health Care Professional Letter Natrecor](https://www.pdfsearch.io/img/5185316126820946af50a5c27f55c87a.jpg) | Add to Reading ListSource URL: www.hc-sc.gc.caLanguage: English - Date: 2013-07-12 14:25:53
|
---|
27![HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ANGIOMAX safely and effectively. See full prescribing information for ANGIOMAX. For patients with Renal Impairment HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ANGIOMAX safely and effectively. See full prescribing information for ANGIOMAX. For patients with Renal Impairment](https://www.pdfsearch.io/img/de770b416cce4a8e6812f04f1012f86c.jpg) | Add to Reading ListSource URL: angiomax.comLanguage: English - Date: 2013-06-20 18:28:46
|
---|
28![C:](https://www.pdfsearch.io/img/c4aa4b235144c2386e4fece0b3c35f42.jpg) |
---|